HemOnc vocabulary relationships

The purpose of this page is to describe the existing relationships in the HemOnc ontology and to give examples. Most of the examples are based on adjuvant CapeOx for colon cancer, as described in the XELOXA study's primary publication (Schmoll et al. 2007, JCO). You can also follow this link to the Concepts page.

Common internal relationships and examples

These relationships occur at least 100 times in the most recent version of the ontology.

Concept Type 1	Relationship	Concept Type 2	Example 1	Relationship	Example 2
Regimen	Can be followed by	Regimen	7 plus 3i (induction)	Can be followed by	HiDAC (consolidation)
Regimen	Can be followed by	Procedure	FEC (neoadjuvant)	Can be followed by	Surgery
Regimen	Can be preceded by	Regimen	HiDAC (consolidation)	Can be preceded by	7 plus 3i (induction)
Regimen	Can be preceded by	Procedure	CapeOx (adjuvant)	Can be preceded by	Surgery
Component	Has accepted use	Condition	Capecitabine	Has accepted use	Colon cancer
Regimen	Has accepted use	Condition	CapeOx	Has accepted use	Colon cancer
Regimen	Has antineoplastic	Component	CapeOx	Has antineoplastic	Capecitabine
Regimen	Has immunosuppressor	Component	Dexamethasone monotherapy	Has immunosuppressor	Dexamethasone
Regimen	Has local therapy	Component	IT Cytarabine & Methotrexate	Has local therapy	Cytarabine
Regimen	Has supportive med	Component	Carboplatin & Pemetrexed	Has supportive med	Dexamethasone
Regimen	Has supportive med	Component Class	Bortezomib monotherapy	Has supportive med	Bisphosphonate
Regimen	Has been compared to	Regimen	CapeOx	Has been compared to	FULV
Regimen	Has been compared to	Regimen Stub	CapeOx	Has been compared to	FUFOX
Component	Has brand name	Brand Name	Capecitabine	Has brand name	Xeloda
Regimen	Has context	Context	CapeOx	Has context	Adjuvant therapy
Component	Has FDA indication	Condition	Capecitabine	Has FDA indication	Colon cancer
Reference	Has first author	Author	XELOXA::00	Has first author	Schmoll_Hans Joachim
Reference	Has middle author	Author	XELOXA::00	Has middle author	Tabernero_Jose M
Reference	Has last author	Author	XELOXA::00	Has last author	Haller_Daniel G
Regimen	Has modality	Modality	CapeOx	Has modality	Chemotherapy
Reference	Has PMID	PubMedURL	XELOXA::00	Has PMID	https://pubmed.ncbi.nlm.nih.gov/17194911
Reference	Has URL	ReferenceURL	XELOXA::00	Has URL	https://ascopubs.org/doi/full/10.1200/jco.2006.08.1075
Reference	Has title	ReferenceTitle	XELOXA::00	Has title	Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients
Regimen	Is current in	Condition	CapeOx	Is current in	Colon cancer
Regimen	Is historical in	Condition	Edrecolomab monotherapy	Is historical in	Colon cancer
Component	Was FDA approved	Year	Capecitabine	Was FDA approved	1998
Reference	Was published in	Journal	XELOXA::00	Was published in	J Clin Oncol
Reference	Was published year	Year	XELOXA::00	Was published year	2007
Regimen	Has cycle	Cycle Sigs	CapeOx	Has cycle	21-day cycle for 8 cycles
Study	Has reference	Reference	XELOXA	Has reference	XELOXA::00
Study	Has reported endpt	Endpoint	XELOXA	Has reported endpt	OS
Study	Had experimental design	Experimental design	XELOXA	Had experimental design	In-class switch
Component	Has route	Route	Capecitabine	Has route	PO
Study	Has study group	Study Group	ECOG E3200	Has study group	Eastern Cooperative Oncology Group
Study	Has study short name	Study name short	XELOXA	Has study short name	Schmoll et al. 2007
Study	Has study type	Study Class	X-ACT	Has study type	FDA registration study
Component	Has sig	Sig	Capecitabine	Has sig	1000 mg/m^2 PO twice per day on days 1 to 14
Component	Has sig	Sig Stub	Capecitabine	Has sig	1660 mg/m^2/day PO on days 1 to 21 (frequency of dosing not specified)
Component Class	Has sig	Sig Stub	Serotonin 5-HT3 antagonist	Has sig	on the day of IV chemotherapy
Component	Is a	Component Class	Capecitabine	Is a	Fluoropyrimidine
Component Class	Is a	Component Class	Fluoropyrimidine	Is a	Pyrimidine analogue
Condition	Is a	Condition	Colon cancer	Is a	Colorectal cancer
Regimen	Is a	Regimen Class	CapeOx	Is a	Platinum doublet
Component	May have route	Route	Dexamethasone	May have route	PO
Regimen	Was studied in	Study	CapeOx	Was studied in	XELOXA
Context	Was studied in	Study	Adjuvant therapy	Was studied in	XELOXA
Condition	Was studied in	Study	Colon cancer	Was studied in	XELOXA

Uncommon internal relationships and examples

These relationships occur less than 100 times in the most recent version of the ontology. This list is currently incomplete.

Concept Type 1	Relationship	Concept Type 2	Example 1	Relationship	Example 2
Context	Is a	Context	Adjuvant therapy	Is a	Post-definitive therapy
Regimen	Has immunosuppressor	Component Class	Fludarabine & Melphalan	Has immunosuppressor	ATG (type not specified)
Regimen	Has been compared to	Procedure	Cisplatin, Fluorouracil, RT	Has been compared to	Surgery
Regimen	Has been compared to	Regimen Class	Ipilimuamb & Nivolumab	Has been compared to	Platinum doublet

Common external relationships and examples

These relationships occur at least 100 times in the most recent version of the ontology.

Concept Type 1	Relationship	Concept Type 2	Example 1	Relationship	Example 2
Regimen	Has antineopl Rx	RxNorm CUI	CapeOx	Has antineopl Rx	194000
Regimen	Has immunosuppr Rx	RxNorm CUI	Dexamethasone monotherapy	Has immunosuppr Rx	3264
Regimen	Has local therap Rx	RxNorm CUI	CHOP-14	Has local therap Rx	3041
Regimen	Has support med Rx	RxNorm CUI	Carboplatin & Pemetrexed	Has support med Rx	3264
Component	Maps to	RxNorm CUI	Capecitabine	Maps to	194000
Condition	Maps to	NCIT CUI	Colon cancer	Maps to	C4910

Uncommon external relationships and examples

These relationships occur less than 100 times in the most recent version of the ontology.

Concept Type 1	Relationship	Concept Type 2	Example 1	Relationship	Example 2
Regimen	Has antineopl Rx	RxNorm Extension CUI	Pixantrone monotherapy	Has antineopl Rx	OMOP997118
Component	Maps to	RxNorm Extension CUI	Pixantrone	Maps to	OMOP997118

Further explanation of some relationships

Can be followed by

This directed relationship is phrased as an optional because there is always the possibility, even in a pre-defined protocol, that the patient will not go on to receive the second (or third, etc.) part of a treatment protocol.

Can be preceded by

This directed relationship is phrased as an optional because it is contextual; in many treatment contexts it is not necessary that the first treatment occurs before the second. In some treatment contexts the relationship is absolute, e.g., chemotherapy given in the adjuvant setting must by definition be preceded by a surgical procedure. This subtle distinction is not yet captured by the ontology.

Has been compared to

This non-directional relationship is the pairwise comparison of two regimens in a randomized clinical trial. In the most common scenario one regimen is a control arm and the other is experimental arm, although this is not always the case.

Has FDA indication

With very few exceptions, the FDA approves drugs, not regimens. Currently, all of these relationships in HemOnc are between components (drugs) and conditions.

Has reported endpt

For "negative" studies, which we define as those having p>0.10 regardless of the predeclared level of alpha, the reported endpoint is the primary endpoint. For "positive" studies, the reported endpoint is that which is the least surrogate with a p<0.10.

Has route and May have route

Components with only one route of administration are related to that route using "Has route". Conversely, components with multiple routes of administration are related to those routes using "May have route".

Has study type

Right now there is only one defined study class: FDA registration trials. We will plan to expand this in the near future to include details such as phase of study, whether a study was a cooperative group trial, etc.

Was replaced by

This is a special relationship type used to associate current and deprecated concepts. For example, "Imatinib monotherapy, high dose" has been replaced by "Imatinib monotherapy" and the replacement is captured by this relationship.